173 related articles for article (PubMed ID: 29385878)
21. Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.
Davies RS; Smith C; Lester JF
Anticancer Res; 2016 Apr; 36(4):1799-803. PubMed ID: 27069162
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor-related micro RNAs in prostate cancer and their role in antiandrogen drug resistance.
Rezaei S; Mahjoubin Tehran M; Sahebkar A; Jalili A; Aghaee-Bakhtiari SH
J Cell Physiol; 2020 Apr; 235(4):3222-3234. PubMed ID: 31599460
[TBL] [Abstract][Full Text] [Related]
23. Utility of novel androgen receptor therapies in the real world: A nuanced approach.
Dhawan M; Ryan CJ
Urol Oncol; 2016 Aug; 34(8):340-7. PubMed ID: 27450893
[TBL] [Abstract][Full Text] [Related]
24. New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?
Wilson L; Tang J; Zhong L; Balani G; Gipson G; Xiang P; Yu D; Srinivas S
J Oncol Pharm Pract; 2014 Dec; 20(6):417-25. PubMed ID: 24243919
[TBL] [Abstract][Full Text] [Related]
25. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.
Schrader AJ; Boegemann M; Ohlmann CH; Schnoeller TJ; Krabbe LM; Hajili T; Jentzmik F; Stoeckle M; Schrader M; Herrmann E; Cronauer MV
Eur Urol; 2014 Jan; 65(1):30-6. PubMed ID: 23849416
[TBL] [Abstract][Full Text] [Related]
26. Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice.
Lahcene H; Aprikian AG; Vanhuyse M; Hu J; Bladou F; Cury F; Kassouf W; Perreault S; Dragomir A
J Oncol Pharm Pract; 2020 Mar; 26(2):293-305. PubMed ID: 30997868
[TBL] [Abstract][Full Text] [Related]
27. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
J Clin Oncol; 2016 Jun; 34(18):2098-106. PubMed ID: 26811535
[TBL] [Abstract][Full Text] [Related]
28. Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
Wang X; Yang H; Hu X; Wang W; Yu X; Wang S; Zhang X; Liu L
J Oncol Pharm Pract; 2021 Apr; 27(3):614-622. PubMed ID: 32529950
[TBL] [Abstract][Full Text] [Related]
29. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
Badrising S; van der Noort V; van Oort IM; van den Berg HP; Los M; Hamberg P; Coenen JL; van den Eertwegh AJ; de Jong IJ; Kerver ED; van Tinteren H; Bergman AM
Cancer; 2014 Apr; 120(7):968-75. PubMed ID: 24382803
[TBL] [Abstract][Full Text] [Related]
30. Overall Survival Among Chemotherapy-Naive Patients With Castration-Resistant Prostate Cancer Under Abiraterone Versus Enzalutamide: A Direct Comparison Based on a 2014-2018 French Population Study (the SPEAR Cohort).
Scailteux LM; Campillo-Gimenez B; Kerbrat S; Despas F; Mathieu R; Vincendeau S; Balusson F; Happe A; Nowak E; Oger E
Am J Epidemiol; 2021 Feb; 190(3):413-422. PubMed ID: 32944756
[TBL] [Abstract][Full Text] [Related]
31. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.
Buttigliero C; Tucci M; Bertaglia V; Vignani F; Bironzo P; Di Maio M; Scagliotti GV
Cancer Treat Rev; 2015 Dec; 41(10):884-92. PubMed ID: 26342718
[TBL] [Abstract][Full Text] [Related]
32. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L
Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193
[TBL] [Abstract][Full Text] [Related]
33. Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden.
George G; Vikman H; Gedeborg R; Lissbrant IF; Garmo H; Styrke J; Van Hemelrijck M; Stattin P
Acta Oncol; 2021 Apr; 60(4):459-465. PubMed ID: 33606571
[TBL] [Abstract][Full Text] [Related]
34. The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study.
Naito Y; Kato M; Kawanishi H; Yuguchi Y; Yuba T; Ishikawa T; Hattori K; Yamamoto A; Sano T; Matsukawa Y; Kimura T; Nishikimi T; Hattori R; Tsuzuki T; Gotoh M
Prostate; 2020 Nov; 80(15):1373-1380. PubMed ID: 32914895
[TBL] [Abstract][Full Text] [Related]
35. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.
Plouznikoff N; Artigas C; Sideris S; Martinez Chanza N; Gil T; Peltier A; Flamen P
Ann Nucl Med; 2019 Dec; 33(12):945-954. PubMed ID: 31587172
[TBL] [Abstract][Full Text] [Related]
37. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Lolli C; De Lisi D; Conteduca V; Gurioli G; Scarpi E; Schepisi G; Ravaglia G; Menna C; Farolfi A; Altavilla A; Burgio SL; Tonini G; Santini D; De Giorgi U
Prostate; 2019 Aug; 79(11):1211-1220. PubMed ID: 31251826
[TBL] [Abstract][Full Text] [Related]
38. The importance of targeting intracrinology in prostate cancer management.
Hamid ARAH; Tendi W; Sesari SS; Mochtar CA; Umbas R; Verhaegh G; Schalken JA
World J Urol; 2019 May; 37(5):751-757. PubMed ID: 30350016
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial.
Siemens DR; Klotz L; Heidenreich A; Chowdhury S; Villers A; Baron B; van Os S; Hasabou N; Wang F; Lin P; Shore ND
J Urol; 2018 Jan; 199(1):147-154. PubMed ID: 28827103
[TBL] [Abstract][Full Text] [Related]
40. The role of enzalutamide in the treatment of castration-resistant prostate cancer.
Rawlinson A; Mohammed A; Miller M; Kunkler R
Future Oncol; 2012 Sep; 8(9):1073-81. PubMed ID: 23030482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
